Form4insider filings, from the source

SEC Form 4 · accession 0001140361-17-036058

Loxo Oncology, Inc. · LOXO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Joshua H. Bilenker
Officer — President & CEO · Director
Period of report
Sep 18, 2017
Accepted (ET)
Sep 20, 2017 · 5:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001581720

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockSep 18, 2017M7,500$1.184A196,207D
Common StockF2,F3Sep 18, 2017S1,104$87.9294D195,103D
Common StockF2,F4Sep 18, 2017S3,379$89.0921D191,724D
Common StockF2,F5Sep 18, 2017S2,817$89.8754D188,907D
Common StockF2,F6Sep 18, 2017S200$90.555D188,707D
Common StockSep 19, 2017M7,500$1.184A196,207D
Common StockF2,F7Sep 19, 2017S2,364$87.8188D193,843D
Common StockF2,F8Sep 19, 2017S2,873$89.0292D190,970D
Common StockF2,F9Sep 19, 2017S2,263$89.4764D188,707D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Employee Stock Option (right to buy)F10$1.184Sep 18, 2017M7,500D—Nov 14, 2023Common Stock7,500142,190D
Employee Stock Option (right to buy)F10$1.184Sep 19, 2017M7,500D—Nov 14, 2023Common Stock7,500134,690D

Explanation of responses